<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2021-3-75-80</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Коморбидность у больных лобулярным панникулитом-липодерматосклерозом</article-title><trans-title-group xml:lang="en"><trans-title>Comorbidity in patients with lobular panniculitis-lipodermatosclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4846-5531</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Егорова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Egorova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Николаевна Егорова</p><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Olga Nikolaevna Egorova</p><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7091-2054</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9797-0182</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сажина</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sazhina</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2021</year></pub-date><volume>15</volume><issue>3</issue><fpage>75</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Егорова О.Н., Белов Б.С., Сажина Е.Г., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Егорова О.Н., Белов Б.С., Сажина Е.Г.</copyright-holder><copyright-holder xml:lang="en">Egorova O.N., Belov B.S., Sazhina E.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1152">https://mrj.ima-press.net/mrj/article/view/1152</self-uri><abstract><p>Липодерматосклероз (ЛДС) – один из вариантов лобулярного панникулита. Дебют ЛДС приходится на возраст 50–60 лет, когда у многих пациентов уже имеется коморбидная патология, требующая комплексной терапии, что оказывает влияние на течение, выбор тактики лечения и прогноз ЛДС, а также на качество жизни.</p><p>Цель исследования – изучение структуры и частоты коморбидных состояний у пациентов с ЛДС.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Обследовано 53 пациента (3 мужчин и 50 женщин) 18–80 лет с верифицированным диагнозом ЛДС, наблюдавшихся в ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» в среднем 10 лет. Продолжительность заболевания варьировалась от 2 нед до 20 лет. При клиническом обследовании определяли локализацию, распространенность, окраску и количество пораженных участков кожи и подкожной жировой клетчатки. Интенсивность боли при пальпации узла оценивали по визуальной аналоговой шкале (ВАШ). Лабораторно-инструментальное исследование включало: анализы крови и мочи, компьютерную томографию органов грудной клетки и ультразвуковую допплерографию нижних конечностей с регистрацией линейной скорости кровотока в заинтересованных венах (бедренных, подколенных, задних большеберцовых, стопы). Клиническое, лабораторное и инструментальное обследование больных осуществляли 2 раза в год. Для оценки взаимосвязи коморбидной патологией с течением ЛДС использовали индексы CIRS и Charlson.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Среди пациентов преобладали женщины (60,3%) с повышенной массой тела (91,5±21,8 кг). В зависимости от длительности заболевания были выделены основные варианты течения ЛДС: острое (&lt;3 мес), подострое (3–6 мес) и хроническое (&gt;6 мес). Изменения кожи ассоциировалось с полиартралгиями (34%) и/или миалгиями (22,6%), преимущественно на стороне пораженной конечности. У 16 пациентов зарегистрировано повышение СОЭ в среднем до 23,8±7,8 мм/ч, у 7 больных в (том числе у 4 с острым течением ЛДС) – более чем трехкратное увеличение уровня СРБ. У 17 пациентов коморбидных заболеваний не выявлено, 64,7% из них были моложе 50 лет и имели острое течение ЛДС (р=0,02). У 68% больных, преимущественно с хроническим течением ЛДС, зафиксирована следующая сопутствующая патология: хроническая венозная недостаточность (ХВН; у 67,9%), экзогенно-конституциональное ожирение (у 60,3%); ревматические заболевания (у 45,2%), в том числе остеоартрит (у 75%), ревматоидный артрит (у 17%), антифосфолипидный синдром (у 8%), а также артериальная гипертензия (у 39,6%). У большинства пациентов имелось 1 сопутствующее заболевание, практически у пятой части – 2. Доля пациентов с 3 коморбидными патологиями составила 11,1%, с 4 – 8,3% и 5 – 5,5%. При оценке индекса Charlson показатель 10-летней выживаемости &gt;90% (значения индекса от 0 до 2 баллов) отмечен у 66% больных, 53–77% (3–4 балла) – у 26,4% и &lt;21% (≥5 баллов) – у 7,5%. Обнаружена взаимосвязь индекса коморбидности с возрастом пациентов (r=0,8, p&lt;0,05), ассоциации с продолжительностью ЛДС не установлено (r=0,3, p=0,2). У больных старше 61 года зафиксировано ≥1 коморбидное состояние. Индекс CIRS для данной группы составлял в среднем 4,2±0,3 балла (0–10), у большинства больных (45,2%) он был &lt;5 баллов. При анализе шкал Charlson и CIRS подтверждена их статистически значимая связь (r=0,5, р=0,0000001).</p></sec><sec><title>Заключение</title><p>Заключение. У больных ЛДС отмечена высокая частота коморбидной патологии. Курация больных требует междисциплинарного подхода и взаимодействия между врачами разных специальностей.</p></sec></abstract><trans-abstract xml:lang="en"><p>Lipodermatosclerosis (LDS) is one of the variants of lobular panniculitis. The onset of LDS falls on the age of 50–60 years, when many patients already have comorbid pathology requiring complex therapy, which affects the course, the choice of treatment and prognosis of LDS, as well as the quality of life.</p><sec><title>Objective</title><p>Objective: to study the structure and frequency of comorbid conditions in patients with LDS.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. 53 patients (3 men and 50 women), 18–80 years old, with a verified diagnosis of LDS were included, all of them had an average follow up of 10 years (they were observed in the V.A. Nasonova Research Institute of Rheumatology). The duration of the disease ranged from 2 weeks to 20 years. During clinical examination, the localization, prevalence, color and number of affected skin areas and sub cutaneous fat were determined. The intensity of pain on palpation of the node was assessed using a visual analogue scale (VAS). Laboratory and instrumental research included: blood and urine tests, computed tomography of the chest and ultrasound Doppler of the lower extremities with registration of the linear blood flow velocity in the affected veins (femoral, popliteal, posterior tibial, foot veins). Clinical, laboratory and instrumental examination of patients was carried out 2 times a year. The CIRS and Charlson indices were used to assess the relationship between comorbid pathology and LDS.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Most patients (60.3%) were women with increased body weight (91.5±21.8 kg). Depending on the duration of the disease, the main variants of the LDS course were: acute (&lt;3 months), subacute (3–6 months), and chronic (&gt;6 months). Skin changes were associated with polyarthralgia (34%) and/or myalgia (22.6%), mainly on the side of the affected limb. In 16 patients, an increase in ESR, on average 23.8±7.8 mm per hour, was detected, in 7 patients, including 4 with an acute course of LDS, – more than a threefold increase in the level of CRP. No comorbid diseases had 17 patients, 64.7% of them were under 50 years and had an acute course of LDS (p=0.02). In 68% of patients, mainly with chronic LDS, the following concomitant diseases was recorded: chronic venous insufficiency (CVI; in 67.9%); exogenous constitutional obesity (in 60.3%); rheumatic diseases (45.2%), including osteoarthritis (75%), rheumatoid arthritis (17%), antiphospholipid syndrome (8%), and arterial hypertension (39.6%). Most patients had 1 concomitant disease, and almost one fifth of patients had 2 concomitant diseases. The proportion of patients with 3 comorbid pathologies was 11.1%, with 4 – 8.3% and with 5 – 5.5%. When assessing the Charlson index, a 10-year survival rate of &gt;90% (index values from 0 to 2 points) was observed in 66% of patients, 53–77% (3–4 points) – in 26.4% and &lt;21% (≥5 points) – in 7.5%. There was correlation between the comorbidity index and the age of patients (r=0.8, p&lt;0.05); no association with the duration of LDS was found (r=0.3, p=0.2). Patients over 61 years had ≥1 comorbid disease. The average CIRS index for this group was 4.2±0.3 points (0–10), in most patients (45.2%) it was &lt;5 points. Analysis of the Charlson and CIRS scales confirmed their statistically significant relationship (r=0.5, p=0.0000001).</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with LDS, a high incidence of comorbid pathology was noted. Interdisciplinary approach with interaction between doctors of different specialties is required for treatment of these patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>панникулит</kwd><kwd>липодерматосклероз</kwd><kwd>коморбидность</kwd><kwd>индекс Charlson</kwd><kwd>шкала оценки коморбидности CIRS</kwd></kwd-group><kwd-group xml:lang="en"><kwd>panniculitis</kwd><kwd>lipodermatosclerosis</kwd><kwd>comorbidity</kwd><kwd>Charlson index</kwd><kwd>scale for assessing comorbidity CIRS</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell-Scherer D. Multimorbidity challenge ofevidence-based medicine. Evid Based Med. 2010 Dec;15(6):165-6. doi: 10.1136/ebm1154.</mixed-citation><mixed-citation xml:lang="en">Campbell-Scherer D. Multimorbidity challenge ofevidence-based medicine. Evid Based Med. 2010 Dec;15(6):165-6. doi: 10.1136/ebm1154.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Гордеев АВ, Галушко ЕА. Ревматические заболевания и многоморбидность. Терапевтический архив. 2015;87(5):4-9.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Gordeev AV, Galushko EA. Rheumatic diseases and multimorbidity. Terapevticheskii arkhiv. 2015;87(5):4-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Вербовая АФ, Цанава ИА, Вербовая НИ. Медицина XXI века: в фокусе коморбидность.Университетская медицина Урала. 2017;(2):27-31.</mixed-citation><mixed-citation xml:lang="en">Verbovaya AF, Tsanava IA, Verbovaya NI. Medicine of the XXI century: comorbidity in focus.Universitetskaya meditsina Urala. 2017;(2):27-31. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Litwin MS, Greenfield S, Elkin EP. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007 May 1;109(9):1777-83. doi: 10.1002/cncr.22615.</mixed-citation><mixed-citation xml:lang="en">Litwin MS, Greenfield S, Elkin EP. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007 May 1;109(9):1777-83. doi: 10.1002/cncr.22615.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Von Korff MA, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992 Feb; 45(2):197-203. doi: 10.1016/0895-4356(92)90016-g.</mixed-citation><mixed-citation xml:lang="en">Von Korff MA, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992 Feb; 45(2):197-203. doi: 10.1016/0895-4356(92)90016-g.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Starfield B, Weiner J, Mumford L. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res. 1991 Apr;26(1):53-74.</mixed-citation><mixed-citation xml:lang="en">Starfield B, Weiner J, Mumford L. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res. 1991 Apr;26(1):53-74.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rozzini R, Frisoni GB, Barbisoni P, et al. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbid¬ity. Age Ageing. 2002 Jul;31(4): 277-85. doi: 10.1093/ageing/31.4.277.</mixed-citation><mixed-citation xml:lang="en">Rozzini R, Frisoni GB, Barbisoni P, et al. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbid¬ity. Age Ageing. 2002 Jul;31(4): 277-85. doi: 10.1093/ageing/31.4.277.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan MH, Feinstein AR. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus. Diabetes. 1973 Mar;22(3):160-74. doi: 10.2337/diab.22.3.160.</mixed-citation><mixed-citation xml:lang="en">Kaplan MH, Feinstein AR. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus. Diabetes. 1973 Mar;22(3):160-74. doi: 10.2337/diab.22.3.160.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Parkerson GR Jr, Broadhead WE, Tse CK. The Duke Severity of Illness Checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol. 1993 Apr;46(4): 379-93. doi: 10.1016/0895-4356(93)90153-r.</mixed-citation><mixed-citation xml:lang="en">Parkerson GR Jr, Broadhead WE, Tse CK. The Duke Severity of Illness Checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol. 1993 Apr;46(4): 379-93. doi: 10.1016/0895-4356(93)90153-r.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Charlson ME, Pompei P, Ales HL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.</mixed-citation><mixed-citation xml:lang="en">Charlson ME, Pompei P, Ales HL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Сарсенбаева ГИ, Турсынбекова АЕ. Современные подходы к оценке коморбидности у пациентов. CardioСоматика. 2019;(1):19-23.</mixed-citation><mixed-citation xml:lang="en">Sarsenbaeva GI, Tursynbekova AE. Modern approaches to the assessment of comorbidity in patients. CardioSomatika. 2019;(1):19-23. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Miller MD, Towers A. Manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburg: University of Pittsburgh; 1991. 31 p.</mixed-citation><mixed-citation xml:lang="en">Miller MD, Towers A. Manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburg: University of Pittsburgh; 1991. 31 p.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Greenfield S, Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: comorbidity and outcomes after hipreplacement. Med Care. 1993 Feb;31(2): 141-54. doi: 10.1097/00005650-199302000-00005.</mixed-citation><mixed-citation xml:lang="en">Greenfield S, Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: comorbidity and outcomes after hipreplacement. Med Care. 1993 Feb;31(2): 141-54. doi: 10.1097/00005650-199302000-00005.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Grolla DL, Tob T, Bombardiere C. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol. 2005 Jun;58(6):595-602. doi: 10.1016/j.jclinepi.2004.10.018.</mixed-citation><mixed-citation xml:lang="en">Grolla DL, Tob T, Bombardiere C. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol. 2005 Jun;58(6):595-602. doi: 10.1016/j.jclinepi.2004.10.018.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003 Mar;56(3):221-9. doi: 10.1016/s0895-4356(02)00585-1.</mixed-citation><mixed-citation xml:lang="en">De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003 Mar;56(3):221-9. doi: 10.1016/s0895-4356(02)00585-1.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Radner H. Multimorbidity in rheumatic conditions. Wien Klin Wochenschr. 2016 Nov; 128(21-22):786-90. doi: 10.1007/s00508-016-1090-x. Epub 2016 Oct 13.</mixed-citation><mixed-citation xml:lang="en">Radner H. Multimorbidity in rheumatic conditions. Wien Klin Wochenschr. 2016 Nov; 128(21-22):786-90. doi: 10.1007/s00508-016-1090-x. Epub 2016 Oct 13.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669. Epub 2009 May 19.</mixed-citation><mixed-citation xml:lang="en">Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669. Epub 2009 May 19.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Панафидина ТА, Кондратьева ЛВ, Герасимова ЕВ и др. Коморбидность при ревматоидном артрите. Научно-практическая ревматология. 2014;52(3):283-9.</mixed-citation><mixed-citation xml:lang="en">Panafidina TA, Kondrat'eva LV, Gerasimova EV, et al. Comorbidity in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2014;52(3):283-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Клюквина НГ. Проблема коморбидности при системной красной волчанке. Русский медицинский журнал. 2015;(7): 370-4.</mixed-citation><mixed-citation xml:lang="en">Klyukvina NG. The problem of comorbidity in systemic lupus erythematosus. Russkii meditsinskii zhurnal. 2015;(7):370-4. (In Russ.].</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Балабанова РМ. Анкилозирующий спондилит и коморбидность: безопасность длительного применения нимесулида. Современная ревматология. 2017;11(4): 79-82.</mixed-citation><mixed-citation xml:lang="en">Balabanova RM. Ankylosing spondylitis and comorbidity: safety of long-term use of nimesulide. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(4):79-82. (In Russ.). doi: 10.14412/1996-7012-2017-4-79-82</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi: 10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.</mixed-citation><mixed-citation xml:lang="en">Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi: 10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. Jul-Aug 2010;23(4):375-88. doi: 10.1111/j.1529-8019.2010.01338.x.</mixed-citation><mixed-citation xml:lang="en">Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. Jul-Aug 2010;23(4):375-88. doi: 10.1111/j.1529-8019.2010.01338.x.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Липодерматосклероз как разновидность лобулярного панникулита: клинические особенности. Клиницист. 2015;(9):28-34.</mixed-citation><mixed-citation xml:lang="en">Egorova ON, Belov BS, Glukhova SI, Radenska-Lopovok SG. Lipodermatosclerosis as a type of lobular panniculitis: clinical features. Klinitsist. 2015;(9):28-34. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 Dec;40(6):1248-52. doi: 10.1016/j.jvs.2004.09.027.</mixed-citation><mixed-citation xml:lang="en">Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 Dec;40(6):1248-52. doi: 10.1016/j.jvs.2004.09.027.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Савельев ВС, Гологорский ВА, Кириенко АИ и др. Флебология. Руководство для врачей. Москва: Медицина; 2001.</mixed-citation><mixed-citation xml:lang="en">Savel'ev VS, Gologorskii VA, Kirienko AI, et al. Flebologiya. Rukovodstvo dlya vrachei [Phlebology. A guide for doctors]. Moscow: Meditsina; 2001.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ocampo VD, Gladman M. Psoriatic arthritis Version 1. F1000Res. 2019 Sep 20; 8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Ocampo VD, Gladman M. Psoriatic arthritis Version 1. F1000Res. 2019 Sep 20; 8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104-10. doi: 10.7326/0003-4819-120-2-199401150-00002.</mixed-citation><mixed-citation xml:lang="en">Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104-10. doi: 10.7326/0003-4819-120-2-199401150-00002.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review. https://seer.cancer.gov/archive/csr/1975_2007/</mixed-citation><mixed-citation xml:lang="en">Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review. https://seer.cancer.gov/archive/csr/1975_2007/</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Никитина НМ, Афанасьев ИА, Ребров АП. Коморбидность у больных ревматоидным артритом. Научно-практическая ревматология. 2015;53(2):149-54.</mixed-citation><mixed-citation xml:lang="en">Nikitina NM, Afanas'ev IA, Rebrov AP. Comorbidity in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2015;53(2):149-54. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Nikitina NM, Afanas'ev IA, Rebrov AP. Comorbidity in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2015;53(2):149-54. (In Russ.).</mixed-citation><mixed-citation xml:lang="en">Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumaticdiseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233. Epub 2016 Mar 16.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumaticdiseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233. Epub 2016 Mar 16.</mixed-citation><mixed-citation xml:lang="en">Frewen J, Hughes AJ, Denny J, Natkunarajah J. Lipodermatosclerosis of the pendulous abdomen. Clin Exp Dermatol. 2020 Jul;45(5):626-7. doi: 10.1111/ced.14210. Epub 2020 Apr 22.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Frewen J, Hughes AJ, Denny J, Natkunarajah J. Lipodermatosclerosis of the pendulous abdomen. Clin Exp Dermatol. 2020 Jul;45(5):626-7. doi: 10.1111/ced.14210. Epub 2020 Apr 22.</mixed-citation><mixed-citation xml:lang="en">Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the framingham study. Comparative Study Am J Epidemiol. 1997 Mar 1;145(5):408-15. doi: 10.1093/oxfordjournals.aje.a009122.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the framingham study. Comparative Study Am J Epidemiol. 1997 Mar 1;145(5):408-15. doi: 10.1093/oxfordjournals.aje.a009122.</mixed-citation><mixed-citation xml:lang="en">Essers I, Stolwijk С, Boonen А, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Multicenter study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi: 10.1136/annrheumdis-2014-206147. Epub 2014 Oct 31.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Essers I, Stolwijk С, Boonen А, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Multicenter study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi: 10.1136/annrheumdis-2014-206147. Epub 2014 Oct 31.</mixed-citation><mixed-citation xml:lang="en">Essers I, Stolwijk С, Boonen А, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Multicenter study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi: 10.1136/annrheumdis-2014-206147. Epub 2014 Oct 31.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
